VCU Massey Cancer Center recognized by U.S. News as Richmond’s only nationally ranked cancer care provider
Virginia Commonwealth University Massey Cancer Center provides the only nationally ranked cancer care in Richmond, Va., according to U.S. News & World Report. For the first time, U.S. News ranked the hospitals in America’s 52 largest metropolitan areas. Ranking at the top of all 20 hospitals in the Richmond metro area is VCU Medical Center, which includes Massey’s oncology patient care.
New biomarker predicts breast cancer relapse
Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body’s immune system that can predict a breast cancer patient’s risk of cancer recurrence. This breakthrough may lead to new genetic testing that further personalizes breast cancer care.
New combination therapy eradicates prostate cancer in vivo
In their study, published in the journal Proceedings of the National Academy of Sciences, prostate cancer growth in mice with functioning immune systems was inhibited by sensitizing the cancer cells with the drug Sabutoclax (BI-97C1) and using UTMD technology to deliver a viral gene therapy that expresses the genemda-7/IL-24. This powerful new approach to treating prostate cancer builds upon prior studies by principle investigator Paul B. Fisher, M.P.H., Ph.D., Thelma Newmeyer Corman Endowed Chair in Oncology Research at VCU Massey (photo on left). Fisher is professor and chair of the Department of Human and Molecular Genetics in the VCU School of Medicine, and director of the VCU Institute of Molecular Medicine.
Discovery in liver cancer cells provides new target for drugs
Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma. Currently, there is virtually no effective treatment for HCC, and this breakthrough identifies a promising new target for therapeutic intervention.
VCU Massey Cancer Center first to combine targeted agents to kill multiple myeloma cells
Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal Blood, are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.